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and Andrew D. Hislop
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Antigen immunodominance is an unexplained feature of CD8
 
 
 
 T cell responses to 
herpesviruses, which are agents whose lytic replication involves the sequential expression of 
immediate early (IE), early (E), and late (L) proteins. Here, we analyze the primary CD8 
response to Epstein-Barr virus (EBV) infection for reactivity to 2 IE proteins, 11 
representative E proteins, and 10 representative L proteins, across a range of HLA 
backgrounds. Responses were consistently skewed toward epitopes in IE and a subset of E 
proteins, with only occasional responses to novel epitopes in L proteins. CD8
 
 
 
 T cell clones 
to representative IE, E, and L epitopes were assayed against EBV-transformed lymphoblastoid 
cell lines (LCLs) containing lytically infected cells. This showed direct recognition of lytically 
infected cells by all three sets of effectors but at markedly different levels, in the order 
IE 
 
 
 
 E 
 
 
 
 L, indicating that the efficiency of epitope presentation falls dramatically with 
progress of the lytic cycle. Thus, EBV lytic cycle antigens display a hierarchy of 
immunodominance that directly reflects the efficiency of their presentation in lytically 
infected cells; the CD8
 
 
 
 T cell response thereby focuses on targets whose recognition leads 
to maximal biologic effect.
 
CD8
 
 
 
 T cells control virus infection by recog-
nizing short peptides derived from the intra-
cellular breakdown of viral proteins and pre-
sented at the infected cell surface by MHC
class I molecules. There is often a marked focus-
ing of CD8
 
 
 
 T cell responses against a small
number of immunodominant viral epitopes
(1–3), and many aspects of peptide generation,
transport, and MHC class I loading have been
considered as potential determinants for epitope
immunodominance (4, 5). However, in more
complex systems where not all viral proteins
may access the MHC class I pathway equally,
the antigen source itself may also be an important
factor. This is particularly the case for herpes-
viruses, where immediate early (IE), early (E),
and late (L) viral proteins are expressed at differ-
ent phases of the replication cycle and where
the antigen-presenting capacity of the infected
cell may itself change as the cycle progresses
(6). Indeed, determining whether there is a
marked hierarchy of immunodominance among
IE, E, and L proteins and whether this is re-
lated to the antigen-processing function of the
lytically infected cells could have implications for
the pathway whereby the virus-specific CD8
 
 
 
 T
cell response is primed.
By definition, hierarchies of immunodomi-
nance should be consistently observed across a
wide range of MHC backgrounds. As a result,
their existence in herpesvirus systems is likely to
emerge more clearly from studies in man, rather
than in mouse models where work tends to focus
on a small number of inbred strains (6–8). Studies
to date on human CD8
 
 
 
 T cell responses to
herpes simplex virus, an 
 
 
 
-herpesvirus, suggest
that they are preferentially directed against late
structural proteins of the virus (9, 10). Likewise
with cytomegalovirus, a 
 
 
 
-herpesvirus, the pp65
viral tegument protein expressed late in lytic
cycle is well established as an immunodominant
antigen (11, 12)—although not to the exclusion
of some more recently discovered IE and E target
proteins (13, 14). However, for both agents the
issue of immunodominance among viral anti-
gens, and the effect that viral immune evasion
proteins might have on immunogenicity in vivo
(6), remains to be fully resolved.
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Abbreviations used: ACV, acy-
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cell line. 
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Here, we turn our attention to EBV, a 
 
 
 
1-herpesvirus
which preferentially infects B lymphocytes. During primary
infection as seen in infectious mononucleosis (IM) patients,
the virus replicates at permissive sites in the oropharynx and
induces a strong CD8
 
 
 
 T cell response to lytic cycle antigens
that dominate the circulating T lymphocyte pool (15, 16).
Although viral epitopes of varying strengths have been iden-
tified within IE and some E proteins examined to date (17–
20), these studies were based on a small number of lytic cycle
proteins or selected epitopes, with virtually no representa-
tion of L antigens as potential targets. This paper describes
two interdependent sets of experiments. In the first, we
screen primary CD8
 
 
 
 T cell responses for reactivities to the
2 IE proteins, 11 representative E, and 10 representative L
proteins and demonstrate the existence of a marked hierar-
chy of immunodominance between these different groups of
antigens. In the second, we use CD8
 
 
 
 T cell clones specific
for representative IE, E, and L epitopes as probes to ask
whether the above hierarchy correlates in any way with the
efficiency of epitope presentation in lytically infected cells.
 
RESULTS
Antigen mapping experiments
 
CD8
 
 
 
 T cell clones were established from in vivo–activated
cells in the blood of acute IM patients by limiting dilution
cloning and their specificity determined in cytotoxicity
assays against autologous target lymphoblastoid cell lines
(LCLs) infected with recombinant vaccinia viruses express-
ing one of the panel of selected EBV lytic cycle proteins.
The 23 targets selected included the 2 IE, 11 representative
E, and 10 representative L proteins (see Materials and meth-
ods). Examples of the range of specificities identified, and the
subsequent mapping of those specificities to individual pep-
tide epitopes are given for two patients (see Figs. 1 and 2).
For patient IM73, responses were directed against just 3
of the 23 target antigens (BRLF1, BMLF1, and BALF2) and
the screening results from clones representing these three re-
activities are shown in Fig. 1 A. Overall, there were 15
clones specific for the IE protein BRLF1, 4 for the E protein
BMLF1, and 7 for the E protein BALF2. Throughout these
experiments, once the relevant HLA-restricting allele had
been identified from a second round of vaccinia assays on
HLA-matched LCL targets, the peptide epitope specificity of
each clone was determined wherever possible. Clones were
tested either against known epitopes derived from the pro-
tein of interest (where such epitopes existed), or against an
overlapping peptide library for the protein (where the library
was available), or against potential epitope predictions based
on the peptide binding motif of the restricting HLA allele.
Fig. 1 B shows the relevant results from all of the antigen-
specific clones derived from IM73. By HLA restriction, the
15 BRLF1-specific clones contained three different reactivi-
ties. Four clones restricted through HLA-A*0201 were
found to recognize a known BRLF1 epitope YVLDHLIVV
(hereafter, all epitopes are subsequently identified by three or
four letter codes as initially underlined); interestingly two
further clones restricted through HLA-A*2402 and nine fur-
ther clones restricted through HLA-C*0202 all mapped to
epitopes encoded within a 15mer BRLF1 peptide IACPIV-
MRYVLDHLI that overlapped, but was distinct from, the
YVL sequence. As for the other reactivities in IM73, all four
BMLF1-specific clones recognized the known HLA-A*0201–
restricted epitope GLCTLVAML, whereas the seven BALF2-
specific clones included four HLA-B*2705–restricted clones
that mapped to a novel epitope ARYAYYLQF found by
screening predicted B27-binding peptides, and three HLA-
B*0702–restricted clones for which no epitope was identi-
fied among predicted B7-binding peptides from the BALF2
sequence.
Fig. 2 shows the corresponding data for a second patient,
IM179, with a broader range of responses. In this case, clonal
reactivities were identified against six different EBV lytic
proteins; these included the IE protein BRLF1 (12 clones),
the E proteins BMRF1 (4 clones), BMLF1 (1 clone) and
BALF2 (4 clones), and the two L proteins BALF4 (4 clones)
and BILF2 (1 clone). HLA restriction and epitope mapping
of the IM179 responses (Fig. 2 B) identified two types of
BRLF1 (IE) reactivity; four HLA-A*0201–restricted clones
were specific for the YVL epitope, and eight HLA-C*0202–
restricted clones recognized the same IACP peptide as seen
by the C*0202-restricted clones from IM73. Of the E anti-
gen–specific responses in IM179, the BMRF1- and BMLF1-
specific clones mapped to known HLA-A*0201–restricted
Figure 1. Assays on EBV-specific CD8  T cell clones from IM 73. 
(A) Representative antigen mapping results from 1 of 15 BRLF1-specific 
clones, 1 of 4 BMLF1-specific clones, and 1 of 7 BALF2-specific clones 
tested on autologous LCL targets preinfected with the panel of 23 recombi-
nant vaccinias expressing individual IE, E, and L proteins of the EBV lytic 
cycle. (B) Epitope mapping results from the 26 EBV lytic antigen-specific 
clones tested on autologous LCL targets preexposed to the BRLF1-derived 
YVL and IACP peptides, to the BMLF1-derived GLC peptide, and to the 
BALF2-derived ARYA peptide (restriction elements as shown). All results are 
expressed as a percentage of specific lysis in 5-h chromium release assays. 
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epitopes in these proteins (TLDYKPLSV and GLC, respec-
tively), whereas the BALF2-specific clones were HLA-
B*2705–restricted and recognized the ARYA 9mer epitope.
The L antigen specificities in IM179 were of particular inter-
est because examples of CD8
 
 
 
 T cell responses to late pro-
teins are extremely rare in the literature (21). The BALF4-
specific clones proved to be HLA-A*0201–restricted and
were mapped by testing predicted peptides to a novel
epitope FLDKGTYTL; the BILF2 reactive clone was re-
stricted by HLA-B*2705 and again was mapped by peptide
prediction to a novel epitope, RRRKGWIPL.
For all patients, clones were established by stimulating
IM PBMCs with a mixture of the 
 
 
 
-irradiated autologous
LCL and pooled allogenic 
 
 
 
-irradiated PBMCs as feeder
cells. Our earlier work had found that, providing IL2 was
available, specific antigen stimulation in vitro was not neces-
sary in order to expand in vivo–activated CD8
 
 
 
 T cells from
the blood of IM patients (18). However, we were concerned
to check whether inclusion of the autologous LCL, which
often contains a small percentage of lytically infected cells, in
the cloning mixture was in some way biasing the range of
specificities obtained. Therefore, in the case of IM179 and of
another patient IM146, parallel clonings were performed us-
ing two substitutes for the autologous LCL; namely, an irra-
diated partially HLA-matched LCL that could not enter lytic
cycle and therefore could not provide any lytic antigen-spe-
cific stimulus (22) or exposure to an anti-CD3 Mab as a pan-T
cell stimulus. In both cases, the range of lytic antigen-specific
clones recovered using these alternative protocols was similar
to that seen using the autologous LCL in the cloning mix
(see Fig. 3’s legend).
A total of 11 acute IM patients, yielding a mean of 20
EBV lytic antigen-specific clones per patient, were studied
in the antigen mapping experiments and Fig. 3 summarizes
the pattern of results obtained. In each case, positive re-
sponses are indicated by shaded boxes and the depth of shad-
ing indicates the proportion of clones that mapped to the an-
tigen in question. Some 9/11 patients responded to one or
both EBV-coded IE proteins; and in five cases, an IE protein
Figure 2. Assays on EBV-specific CD8  T cell clones from IM 179. 
(A) Representative antigen mapping results from 1 of 12 BRLF1-specific 
clones, 1 of 4 BMRF1-specific clones, 1 BMLF1-specific clone, 1 of 4 
BALF2-specific clones, 1 of 4 BALF4-specific clones, and 1 BILF2-specific 
clone. (B) Epitope mapping results from the 26 EBV lytic antigen–specific 
clones tested on autologous LCL targets preexposed to the BRLF1-derived 
YVL and IACP peptides, to the BMRF1-derived TLD peptide, to the BMLF1-
derived GLC peptide, to the BALF2-derived ARYA peptide, to the BALF4-
derived FLD peptide, and to the BILF2-derived RRRK peptide (restriction 
elements as shown). Results expressed as in Fig. 1.
 
Table I. 
 
EBV lytic cycle antigens and epitopes identified by 
CD8
 
 
 
 T cell clones
 
Temporal 
expression
EBV
antigen
Epitope
coordinates Epitope sequence
HLA
allele Reference
 
IE BZLF1 190–197 RAKFKQLL B*0801 (54)
101–115 LQHYREVAA C*0802 New
BRLF1 109–117 YVLDHLIVV A*0201 (55)
148–156 RVRAYTYSK A*0301 (56)
91–99 AENAGNDAC B*4501 New
101–115 IACPIVMRYVLDHLI A*2402 New
 
a
 
101–115 IACPIVMRYVLDHLI C*0202 New
 
a
 
E BMLF1 280–288 GLCTLVAML A*0201 (17, 18)
BMRF1 268–276 YRSGIIAVV B*3906 New
86–100 FRNLAYGRTCVLGK C*0304 (18)
 
a
 
208–216 TLDYKPLSV A*0201 (16)
116–128 RPQGGSRPEFVKL B*0702 New
20–28 CYDHAQTHL A*2402 New
BALF2 418–426 ARYAYYLQF B*2705 New
ND ND B*0702 New
ND ND C*0702 New
ND ND B*1401 New
ND ND B*4501 New
BALF5 ND ND A*0201 New
ND ND A*0301 New
ND ND B*4501 New
BHLF1 ND ND A*0201 New
ND ND B*1501 New
BGLF4 ND ND C*0101 New
BNLF2b ND ND B*1401 New
L BALF4 276–284 FLDKGTYTL A*0201 New
BILF2 240–248 RRRKGWIPL B*2705 New
BBRF1 ND ND A*0201 New
 
a
 
Minimal epitope to be determined. 
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was the immunodominant target. In addition, all 11 patients
responded to one or more of the E proteins and, in six cases,
these were the dominant responses. Interestingly, the great
majority of E protein–specific clones that were detected
mapped to a particular subset of target proteins, namely
BMRF1, BMLF1, BALF2, and BALF5. In contrast, L pro-
tein–specific responses were detected in only 3/11 patients
and, in every case, these responses (to BALF4 in two pa-
tients, and to BILF2 and BBRF1 each in one patient) were
represented by only a small number of clones. Table I gives
the full range of EBV antigen/HLA class I combinations that
were recognized by T cell clones in these experiments. The
majority of these responses are novel and, in 10 cases, led to
the identification of new CD8 epitopes. Of the immuno-
dominant subset of IE and E antigens (BZLF1, BRLF1,
BMLF1, BMRF1, BALF2, BALF5), all but one (BMLF1)
contained between two and six epitopes, whereas responses
to other E antigens or to any of the L antigens were almost
all detected as isolated reactivities to a single epitope.
 
Antigen presentation experiments
 
A system to examine CD8
 
 
 
 T cell recognition of
lytically infected cells.
 
We next sought to establish a means
of assaying IE, E, and L antigen–specific CD8
 
 
 
 T cell re-
sponses for their ability to recognize lytically infected tar-
get cells. The lack of a permissive in vitro system for EBV
replication has meant that this could never be addressed in
conventional cytotoxicity assays. However, the use of IFN 
 
 
 
release as an alternative readout of CD8
 
 
 
 T cell function
allowed the development of an ELISPOT assay where ef-
fector clones were challenged with the appropriately HLA-
matched LCL targets in which the percentage of cells spon-
taneously entering lytic cycle (usually 2–5%) could be
determined by lytic antigen–specific mAb staining. These
lines were established with a recombinant wild-type EBV
and are referred to as BZLF1
 
 
 
 LCLs. Essential control tar-
gets in all of these experiments were BZLF1
 
 
 
 LCLs estab-
lished from the same HLA-matched donors using a recombi-
nant EBV deleted for the BZLF1 IE gene and, therefore,
incapable of entering lytic cycle.
Fig. 4 illustrates two types of experiments that have been
conducted with all the lytic antigen–specific clones used in
this work. These particular experiments used HLA-B*0801–
derived clones specific for the IE epitope RAKFKQLL de-
rived from BZLF1. In the first experiment, inspection of
ELISPOT plates showed clear recognition of an HLA-
B*0801–positive BZLF1
 
 
 
 LCL but not of the matching
BZLF1
 
 
 
 target (Fig. 4 A). Additional targets were recon-
structed mixtures of BZLF1
 
 
 
 LCL cells in which 1, 2, or
5% of the cells had been previously loaded with an optimal
concentration of epitope peptide, washed well, and added
back. Clearly, these mixtures also induced IFN 
 
 
 
 release
from the CD8
 
 
 
 T cell clones, thereby confirming the sensi-
tivity of the assay. The counts of spot-forming cells per well
are shown as histograms in Fig. 4 B. A second type of exper-
iment sought to determine whether positive responses to the
BZLF1
 
 
 
 LCL actually reflected direct recognition of the
lytically infected subpopulation or recognition of the antigen
that had been released from the lytically infected cells, taken
up, processed, and re-presented via the class I pathway by
neighboring latently infected cells in the culture. To dis-
criminate between the two possibilities, a BZLF1
 
 
 
 but
HLA-B*0801–negative “donor” LCL was cocultured for 7 d
with the BZLF1
 
 
 
, HLA-B*0801–positive “recipient” LCL,
and then the mixture was used as a target in the ELISPOT
assay. As shown by the results (Fig. 4, C and D), there was
no recognition of the mixed LCL targets even though re-
cipient cells were clearly still present in the coculture and
were able to present RAK peptide exogenously loaded
on the mixed LCL cell population immediately before the
ELISPOT assay. This indicates that recognition of the
BZLF1
 
 
 
, HLA-B*0801–positive LCL target line by RAK-
specific T cells reflects the presentation of endogenously ex-
pressed antigen by lytically infected cells themselves and does
not result from antigen transfer and cross-presentation within
the culture.
Figure 3. Summary of antigen mapping data from 11 acute IM 
patients (HLA class I types shown). A mean of 20 EBV-specific clones 
were analyzed per patient. For each patient, the EBV lytic antigens recog-
nized by CD8  T cell clones are identified as shaded boxes, and the per-
centage of CD8  T cell clones from each donor recognizing each target 
antigen is reflected by the intensity of the shading. Note that in two cases, 
IM 179 and IM 140, clonings were also performed without  -irradiated 
autologous LCL feeders, either using a  -irradiated allogeneic BZLF1-LCL 
feeder that could not provide any lytic antigen–specific stimulus or using 
an anti-CD3 mAb as a pan-T cell stimulus. Both protocols yielded the same 
spectrum of antigen specificities in proportions that were not significantly 
different from those illustrated above. Combining the results from these 
alternative protocols, for IM 179 (of 20 clones) 50% clones were IE antigen 
specific, 25% clones E antigen specific, and 25% clones L antigen specific; 
for IM 140.1, (of 30 clones) 90% clones were IE antigen specific and 10% 
E antigen specific. 
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LCL recognition by IE, E, and L antigen–specific CD8
 
 
 
T cells. 
 
Using this approach, we set out to examine the
efficiency with which epitopes from different temporal
phases of the EBV replication cycle were presented. Multiple
CD8
 
 
 
 T cell clones to each of three IE epitopes, the
HLA-B*0801–restricted RAK and HLA-B*3501–restricted
EPLPQGQLTAY epitopes both from BZLF1 and the HLA-
A*0201–restricted YVL epitope from BRLF1, were tested
against appropriately HLA-matched BZLF1
 
 
 
 and BZLF1
 
 
 
LCL pairs and representative results are shown in Fig. 5. For
all three epitope specificities, there was consistently good
recognition of the lytic antigen–expressing target cell line,
usually at levels equivalent to those seen on reconstructed
targets in which between 2 and 5% of the control BZLF1
 
 
 
LCL had been preloaded with epitope peptide. In each case,
control experiments were performed using appropriate do-
nor and recipient cell mixtures as described in Fig. 4 (C and
D) and again gave no evidence of antigen transfer and cross-
presentation (not depicted).
Parallel experiments looking at the presentation of E an-
tigens were performed using CD8
 
 
 
 clones specific for the
BMLF1-derived GLC epitope and the BMRF1-derived
TLD epitope, both restricted through HLA-A*0201, and
the BALF2-derived ARYA epitope restricted through
B*2705. As before, several independently derived clones for
each epitope were incubated with appropriate BZLF1
 
 
 
 and
BZLF1
 
 
 
 LCL pairs and recognition assayed by ELISPOT.
As illustrated in Fig. 6 using representative clones to each of
the epitopes, significant recognition was observed in each
case but only at levels equivalent to or less than those seen in
reconstructed targets with 1% peptide-loaded cells. The ap-
parently lower levels of E antigen compared with IE antigen
recognition could not be explained by reduced numbers of
lytically infected cells in the BZLF1
 
 
 
 LCL targets because
the assays in Fig. 6 used the same target lines as used for the
EPL- and YVL-specific effectors in Fig. 5. Again donor and
recipient LCL mixing experiments gave no evidence of E
antigen transfer within cocultures (not depicted).
Although CD8
 
 
 
 T cell responses to viral proteins ex-
pressed at the late stage of EBV replication are rare, we were
able to carry out similar experiments with three clones spe-
cific for the BALF4-derived FLD epitope restricted through
HLA-A*0201 and two clones specific for the BILF2-derived
RRRK epitope restricted through HLA-B*2705; for each
epitope, the clones were derived from two different donors.
Representative results in Fig. 7 show that the L antigen–spe-
cific T cell recognition is detectable only at very low lev-
els—well below that seen against reconstructed targets in
which 1% of the cells had been loaded with epitope peptide.
Importantly, we observed these results despite the fact that
Figure 4. Antigen presentation assays using two CD8  T cell clones 
specific for the BZLF1-derived RAK peptide (HLA-B*0801 restricted). 
A and B show data from an ELISPOT assay on the BZLF1  LCL in which 4% 
cells expressed lytic cycle antigens, on a paired BZLF1  LCL from the same 
HLA-B*0801–positive donor, and on the BZLF1  LCL in which 1, 2, or 5% 
of cells had been preexposed to the RAK peptide. C and D show data from 
an ELISPOT assay on the above BZLF1  and BZLF1  LCLs, on a BZLF1  
LCL from a HLA-B*0801–negative donor (HLA mismatch) and on a mixture 
of the BZLF1  HLA-B*0801–positive LCL and the BZLF1  HLA-B*0801–
negative LCL that had been cocultured for 7 d before the assay and then 
used as targets either without further manipulation or exposed to the RAK 
peptide immediately before the assay. (A and C) The original ELISPOT plate 
is shown alongside the histogram recording the number of spot-forming 
cells observed (B and D). 
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mAb staining against one of the target antigens, BALF4,
confirmed that some 4–5% of the cells in these particular
BZLF1
 
 
 
 LCLs were indeed in late lytic cycle. To ensure
that the result was not an artifact of working with B95.8 vi-
rus–transformed cell lines (23), we repeated the assays using
HLA-A*0201– or HLA-B*2705–positive LCLs carrying
other wild-type EBV strains and confirmed that these were
also poorly recognized by the L epitope–specific effectors
despite the presence of significant numbers of cells in lytic
cycle (unpublished data). As a further control, BZLF1
 
 
 
LCLs were cultured in acyclovir (ACV) to block late lytic
protein production and recognition was indeed abolished
(Fig. 7, ACV); this contrasted with the results observed using
IE or E antigen–specific clones where ACV treatment had
no effect on BZLF1
 
 
 
 LCL recognition (unpublished data).
The possibility of antigen cross-presentation within LCL
cultures is particularly relevant for antigens such as BALF4
and BILF2, as these proteins are present within virus particles
themselves; however, we again observed no cross-presenta-
tion in donor and recipient LCL mixtures, suggesting that
the above experiments were indeed measuring L epitope
presentation by lytically infected cells.
 
Comparing LCL recognition by IE, E, and L antigen–specific 
clones of known avidities
 
Throughout such experiments, we checked in parallel the
functional avidity of the various effector T cell clones by
titration in ELISPOT assays on appropriately matched
BZLF1
 
 
 
 LCLs preloaded with 10-fold dilutions of epitope
peptide in the 10
 
 
 
5
 
–10
 
 
 
13
 
 M range. We found that IE
epitope–specific clones gave 50% optimal recognition at 10
 
 
 
9
 
to 5 
 
 
 
 10
 
 
 
10
 
 M peptide concentrations, which was similar to
the E epitope–specific clones with 50% endpoints 
 
 
 
10
 
 
 
9
 
 M.
Figure 5. Antigen presentation assays using IE antigen–specific 
CD8  T cell clones. Clones specific for the BZLF1-derived EPL (HLA-B*3501 
restricted) and RAK (HLA-B*0801 restricted) epitopes and the BRLF1- 
derived YVL (HLA-A*0201 restricted) epitope were tested in ELISPOT assays 
against pairs of BZLF1  and BZLF1  LCLs with the relevant HLA class 
I–restricting allele (where 5, 10, and 5% of the BZLF1  LCL cells, respec-
tively, were in lytic cycle) and on the BZLF1-LCL in which 1, 2, or 5% of 
cells had been preexposed to the epitope peptide. Results are shown as the 
number of spot-forming cells per well, and the error bars represent 1 SD. 
Data from the two EPL-specific clones are representative of results obtained 
on the only available HLA-B*3501–positive LCL pair. Data from the two 
RAK-specific clones and the two YVL-specific clones are in each case 
representative of results obtained from three clones of each specificity 
tested on three different LCL pairs.
Figure 6. Antigen presentation assays using E antigen–specific 
CD8  T cell clones. Clones specific for the BMLF1-derived GLC (HLA-A*0201 
restricted), the BMRF1-derived TLD (HLA-A*0201 restricted) and the 
BALF2-derived ARYA (HLA-B*2705 restricted) epitopes were assayed as in 
Fig. 5; in each case, 5% of the BZLF1  LCL cells were in lytic cycle. Data 
from the two GLC-specific and TLD-specific clones are each representative 
of results obtained for three epitope-specific clones tested on two differ-
ent HLA-A*0201–positive LCL pairs, and data from the two ARYA-specific 
clones are representative of results obtained from four such clones on two 
different HLA-B*2705–positive LCL pairs. 
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Interestingly, all five clones specific for L epitope specificities
FLD and RRRK were reproducibly more avid with 50%
endpoints between 2 
 
 
 
 10
 
 
 
10
 
 and 10
 
 
 
11
 
 M peptide. There-
fore, it seemed very unlikely that poor LCL recognition
by the latter clones could be ascribed to low avidity. To
check this further, different epitope-specific clones restricted
through the same HLA allele were tested together on the
same BZLF1
 
 
 
 and BZLF1
 
 
 
 LCL target pairs, and their
avidity was simultaneously determined on the peptide-loaded
BZLF1
 
 
 
 LCL. Fig. 8 presents the results of one such experi-
ment involving HLA-A*0201–restricted clones to the YVL
(IE), GLC (E), and FLD (L) epitopes and involving HLA-
B*2705–restricted clones to the ARYA (E) and RRRK
(L) epitopes, all of which were tested on the same pair of
HLA-A*0201–, HLA-B*2705–positive LCLs; because the
BZLF1
 
 
 
 LCL member of the pair showed that 5% of cells
were in the lytic cycle, the reconstructed target used had 5%
BZLF1
 
 
 
 LCL cells preloaded with the relevant epitope pep-
tide. The HLA-A*0201–restricted clones reproduced the fa-
miliar pattern of results in which LCL recognition through
the IE epitope was more efficient than through the E
epitopes, and both were more efficient than through the L
epitope. Yet, the L epitope (FLD)–specific effector clone was
clearly the most avid in the peptide titration assay, with 50%
optimal recognition at a peptide concentration (10
 
 
 
11
 
 M) that
was 50–100-fold lower than that for the IE and E epitope–
specific clones (Fig. 8 A). Likewise with the HLA-B*2705–
restricted clones, the ARYA (E) epitope–specific clone showed
much better LCL recognition than the RRRK (L) epitope–
specific clones even though the latter had a significantly
higher avidity by peptide titration (Fig. 8 B).
 
DISCUSSION
 
There is still relatively little known about hierarchies of im-
munodominance among antigens expressed during a viral
infection. This reflects both the logistic problems of analyz-
ing responses across a large range of MHC alleles and the fact
that viruses with large coding capacities, which are most
likely to display such hierarchies, are the most difficult to an-
alyze comprehensively. Here, we address the question in the
context of EBV, a large human  1-herpesvirus which has
the capacity to encode  70 lytic cycle proteins expressed in
three temporal stages: 2 IE followed by  30 E followed by
 30 L proteins. For this purpose, we expanded the small
target antigen panel used in earlier work (18) to include the
two IE proteins, 11 representative E and 10 representative L
proteins, selected so that the sum of unique E and L se-
quences being screened was roughly equivalent and that the
L proteins included virus capsid, tegument and envelope
components. The results show a clear focusing of CD8  T
cell responses toward epitopes drawn from the two IE and
just four of the E proteins. The trend is consistent with all 11
donors analyzed and is based on the identification of 28 dif-
ferent lytic antigen-specific responses restricted through a to-
tal of three HLA-A, seven HLA-B, and four HLA-C alleles.
Our work exploited the fact that primary infection in IM
is associated with the activation of a large lytic antigen–spe-
cific response (15, 16, 18, 19) that can be directly cloned in
vitro (16, 18). Good correlations have been found between
the range of clones generated in this way and the epitope-
specific response as monitored by HLA class I peptide tet-
ramer staining of IM T cells ex vivo (16). However, it is
possible that our screening assays, based on representative
rather than the full panel of E and L proteins, may have
missed responses to immunodominant antigens not included
in the screen. Nevertheless, the consistent pattern of results
obtained from different patients with different HLA back-
grounds, added to more limited data from an earlier study
(18), suggests that the hierarchy of immunodominance ob-
served is indeed real. The relationship between immuno-
dominance and time of antigen expression in the lytic cycle
is further emphasized by the fact that, of the four most com-
monly recognized antigens within the E protein group,
BMLF1 and BMRF1 are proteins whose synthesis is directly
induced by the BZLF1 and BRLF1 IE transactivators (24–
27), whereas BALF5, and potentially also BALF2, synthesis
is induced by BRLF1 acting in concert with cellular tran-
scription factors (28). Therefore, the expression of such pro-
teins would be among the first markers of progression into
early phase.
We then asked to what extent these lytic antigen–spe-
cific responses are capable of recognizing lytically infected
cells, which is an issue that could never be addressed by
conventional cytotoxicity assays as there is no fully permis-
Figure 7. Antigen presentation assays using L antigen–specific CD8  
T cell clones. Clones specific for the BALF4-derived FLD (HLA-A*0201 
restricted) and the BILF2-derived RRRK (HLA-B*2705 restricted) epitopes 
were assayed as in Fig. 5; for each set of effectors, 4% of the BZLF1  LCL 
cells were in late lytic cycle. These assays also included the ACV-treated 
BZLF1  LCL (with no cells in late lytic cycle) as an additional target (ACV). 
Data from the FLD-specific clones are representative of results from three 
such clones tested on two different HLA-A*0201–positive LCL pairs, and 
data from the two RRRK-specific clones are representative of results ob-
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sive system supporting virus replication in vitro. The alter-
native approach, based on ELISPOT detection of IFN  re-
lease, is well suited to situations where only a small fraction
of the target cell population expresses cognate antigen. Us-
ing the paired BZLF1  LCLs as negative controls, our data
reproducibly show recognition of BZLF1  LCLs that is
strong for IE effectors, slightly weaker for E effectors and
poor for L effectors. This pattern of results cannot be ex-
plained by differences in the functional avidities of the
clones; indeed, it was notable that all five L epitope–specific
clones obtained had the highest avidities of all the lytic
epitope-specific clones expanded from IM blood. Further-
more, these results must reflect direct recognition of lyti-
cally infected cells because experiments using appropriate
mixtures of donor and recipient LCLs as targets failed to
show any evidence of the intercellular transfer and cross-
presentation of lytic cycle antigens in vitro. We believe that
this is a significant negative result because essentially similar
experiments have successfully detected intercellular transfer
of EBV antigens into the HLA class II–processing pathway
(unpublished data; Taylor, G.S., personal communication).
Therefore, although LCLs can present exogenously ac-
quired antigen to CD8  T cells if the antigen is supplied at
sufficiently high concentrations (29–31), the process does
not appear to make a significant contribution to lytic anti-
gen presentation in LCL cultures.
The present data strongly suggest that the efficiency of
antigen presentation in EBV-infected cells falls progressively
during lytic cycle transit. This is interesting in view of the
recent finding that HLA class I levels at the surface of LCL
cells in lytic cycle are on average four- to fivefold lower than
those on the coresident latently infected population (32). In
that study, it was notable that a small fraction of BZLF1-
stained cells retained good HLA class I expression, which is
consistent with the view that antigen presentation is intact at
the initiation of lytic cycle and begins to fall in the
early phase. Importantly, even though BZLF1 and BRLF1
proteins are detectable by immunofluorescence staining
throughout the IE, E, and most of the L phases in lytically
infected cells (33), their mRNA transcripts are present only
during the short IE phase (34) and so de novo synthesis of
these antigens is limited to that period. Because defective
products of de novo synthesis (rather than the products of
mature protein turnover) are now thought to be the major
source of antigens furnishing the MHC class I pathway (35,
36), this would explain why IE-derived epitopes appear to
be well presented on cells throughout the lytic cycle. Like-
wise, those E proteins such as BMLF1 and BMRF1, whose
Figure 8. Comparative antigen presentation and functional avidity 
assays using representative CD8  T cell clones specific for IE, E, and L 
protein–derived epitopes. (A) HLA-A*0201–restricted epitopes, YVL from 
the IE protein BRLF1, GLC from the E protein BMLF1, TLD from the E pro-
tein BMRF1, and FLD from the L protein BALF4, and (B) HLA-B*2705–
restricted epitopes, ARYA from the E protein BALF2 and RRRK from the 
L protein BILF2. In each case, the top half of the figure shows the results 
of peptide titration assays (performed on a peptide-loaded BZLF1  LCL) 
plotting number of spot-forming cells against peptide concentration; this 
allows functional avidity of the CD8  T cell clone to be determined as the 
peptide concentration mediating 50% optimal recognition. The bottom 
half of the figure in each case shows the results of antigen presentation 
assays on a pair of BZLF1  and BZLF1  LCL target cells (where 5% of the 
BZLF1  LCL cells were in lytic cycle) and on the BZLF1  LCL in which 5% 
cells had been loaded with epitope peptide. Note that these results are 
from a single experiment in which all 7 clones were tested simultaneously 
on the same BZLF1  and BZLF1  LCL pair derived from a HLA-A*0201, 
B*2705-positive donor, and titrated on the same BZLF1  LCL loaded with 
cognate peptide. Data are expressed as in Fig. 5. JEM VOL. 201, February 7, 2005 357
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expression is directly activated by the IE proteins, are likely
to be synthesized at a time when the HLA class I presenta-
tion pathway is still relatively intact. Thereafter, antigen pre-
sentation becomes less efficient, as the present experiments
with L antigen–specific effectors show. It is not yet known
whether this is a nonspecific consequence of lytic cycle tran-
sit or evidence of an active EBV immune evasion mecha-
nism, which is analogous to those seen in some  -,  -, and
 2-herpesviruses (37–39). In opposition to the nonspecific
cytopathic effect theory is the fact that cells remain viable
even late in the EBV lytic cycle in vitro (40). Furthermore,
HLA class I down-regulation on lytically infected LCL cells
was not accompanied by a loss of other B cell surface mole-
cules and was equally apparent on cells whose entry into the
late phase was blocked by acyclovir (32), thus, raising the
possibility that an early lytic cycle gene product is actively
targeting the HLA class I antigen-processing pathway.
Our experiments revealed a striking correlation between
the hierarchy of immunodominance among EBV lytic cycle
antigens for CD8  T cell responses (Figs. 1–3) and the effi-
ciency with which these antigens are processed and presented
to CD8  T cells in lytically infected cells (Figs. 4–8). This fo-
cusing of the response on IE and a subset of E proteins ex-
pressed early in the lytic cycle, at a time when processing
function remains relatively intact, is likely to maximize the
effectiveness of CD8  T cell control recognizing and remov-
ing lytically infected cells before they progress to the point at
which infectious virions are produced. It is interesting to
contrast this situation with that seen for other human herpes-
viruses. The human CD8  T cell response to HSV, an
 -herpesvirus predominantly replicating in skin and mucosal
epithelium, is still quite poorly characterized; however, the
evidence to date, at least for HSV type 2, suggests that virus
structural proteins of the late lytic cycle constitute some of
the major targets (9, 10). CMV, a  -herpesvirus with a wider
cell tropism, is more closely studied and its immunodominant
antigens include late structural proteins—in particular the
pp65 tegument component—as well as some IE and E pro-
teins (11–14). Given these differences, we infer that immu-
nodominance hierarchies in antigenically complex viral sys-
tems may not follow a common pattern but may be unique
to each agent, reflecting the particular biology of infection by
that agent in vivo. Key determinants are likely to be the iden-
tity and location of the cells replicating virus during primary
infection, the extent to which viral immune evasion mecha-
nisms affect antigen presentation in these cells, and the rela-
tive importance of cross-priming versus direct priming (41,
42) in the induction of CD8  T cell responses.
In the specific context of EBV, it is still not clear
whether the initial focus of virus replication in the orophar-
ynx involves mucosal epithelium or B lymphocytes as the
most important permissive cell type (43). Resolving this
could have an impact on the question of priming pathways,
because virus replication at localized epithelial sites would
imply a necessity for cross-priming, whereas mucosa-associ-
ated B cell–replicating virus might be able to directly prime
the response. The present results are interesting in this re-
gard. Cross-priming, a process in which viral proteins shed
from infected cells at the site of replication are acquired as
exogenous antigen by local dendritic cells and then pre-
sented to the T cell repertoire (41, 42), might be expected to
induce responses against a broad range of lytic cycle antigens,
including the abundantly expressed late structural proteins of
the virus. Superficially this seems at odds with the marked
focusing of responses that is actually observed. However a
broad range of responses might indeed be induced very early
after EBV infection but, as the IE and E antigen–specific
components restrict the movement of cells into late lytic cy-
cle, the antigen supply would favor the selective expansion
of those same components and produce the narrow spectrum
of responses seen by the time the infection becomes clini-
cally manifest as IM. Nevertheless, the concordance de-
scribed here between antigen immunodominance and the
efficiency of antigen presentation on lytically infected cells is
particularly striking and this leaves open the possibility that
the marked CD8  T cell response to this B-lymphotropic
virus is indeed directly primed.
MATERIALS AND METHODS
Selection of EBV target proteins and generation of vaccinia re-
combinants. The following EBV lytic cycle proteins (number of amino
acid residues identified in brackets) were selected for study: the 2 IE proteins,
BZLF1 (245) and BRLF1 (605); 11 representative E proteins, BMLF1 (438),
BMRF1 (404), BALF2 (1120), BALF5 (1015), BGLF4 (455), BHLF1 (660),
BHRF1 (191), BARF1 (221), BNLF2a (60), BNLF2b (101), and BLLF2
(148); and 10 representative L proteins, BCRF1 (170), BILF1 (312),
BNRF1 (1318), BVRF2 (605), BBRF1 (613), BLLF1 (907), BALF4 (857),
BXLF2 (706), BDLF3 (234), BILF2 (248). The E and L proteins were cho-
sen to be directly comparable in size range and to include a range of different
functions (44). Thus, the E proteins included transcriptional transactivators
(BMLF1 and BMRF1), known or presumed components of the viral DNA
replication machinery (BALF2, BALF5, BGLF4, and BHLF1), a bcl2 homo-
logue (BHRF1), a secreted protein (BARF1), and proteins of unknown
function (BNLF2a, BNLF2b and BLLF2). The L proteins included virus
capsid and tegument components (BNRF1, BVRF2, and BBRF1), known
or presumed viral glycoproteins (BILF1, BILF2, BLLF1, BALF4, BXLF2,
and BDLF3), and a secreted IL-10 homologue (BCRF1). The relevant EBV
(B95.8 strain) genes were expressed from vaccinia virus vectors either as pre-
viously described (18, 45–48) or using the WR strain to express BARF1,
BDLF3, and BXLF2, the RB12 strain (49) to express BNLF2a, BNLF2b,
BILF1, BILF2, BLLF2, and BALF4, or the modified vaccinia Ankara (MVA)
strain (50) to express BBRF1, BVRF2, and BNRF1. For RB12 and MVA
recombinants the EBV genes were tagged at their 3  end with sequences en-
coding an antibody-defined epitope from the influenza virus hemagglutinin
protein and expression of the relevant protein confirmed by immunoblotting
with the epitope-specific antibody.
IM patients. 30–60–ml blood samples were collected from serologically
confirmed cases of acute IM under protocols approved by the South Bir-
mingham Research Ethics Committee. Most PBMCs were cryopreserved
until required, but some were used to generate an EBV-transformed B LCL
by culturing cells in standard culture medium (RPMI-1640, 2 mM gluta-
mine, 100 IU/ml penicillin, 100  g/ml streptomycin, and 10% [vol/vol]
FCS) supplemented with 0.1  g/ml cyclosporin A either without the addi-
tion of exogenous virus (spontaneous transformation by the patient’s resi-
dent virus) or after exposure to B95.8 strain EBV. Patients’ HLA types were
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T cell cloning, antigen mapping, and epitope identification. CD8 
T cell clones were generated from the blood of IM patients by limiting dilu-
tion cloning of PBMCs at 0.3 and 3 cells/well in standard culture medium
supplemented with IL-2 as described previously (18); pooled  -irradiated al-
logeneic PBMCs (105 cells/well) were always included as feeders, usually
with  -irradiated cells (104 cells/well) of the autologous LCL. In some ex-
periments, the autologous LCL was replaced (a) by  -irradiated cells of a par-
tially HLA-matched LCL transformed with an EBV strain incapable of lytic
cycle entry (see next paragraph) and (b) by exposure to an anti-CD3 mAb
OKT3 at 30 ng/ml. Clones with specific cytotoxicity against EBV antigens
were identified in standard 5-h chromium release assays by testing on EBV-
transformed B LCL targets (autologous and allogeneic HLA class I matched)
preinfected with recombinant vaccinias expressing one of a series of individ-
ual EBV lytic cycle antigens as described previously (18). Where possible, the
epitope specificity of the clones was identified first by testing on HLA-
matched LCL cells preexposed to each of a panel of peptides (15-mer over-
lapping by 10, used at 5  g/ml) representing the primary sequence of the
relevant EBV-antigen (B95.8 strain), and then by testing shorter peptides
within the 15-mer of interest at a range of peptide concentrations. When a
library of overlapping peptides was not available, epitope prediction analysis
was conducted on the relevant protein sequence using both the HLA Pep-
tide Binding Predictions program from the Bioinformatics and Molecular
Analysis Section (http://bimas.dcrt.nih.gov/molbio/hla_bind) (51), and the
SYFPEITHI database (52). Predicted epitopes were synthesized and used to
sensitize target cells in cytotoxicity assays as above. Peptides were purchased
from Alta Biosciences and dissolved in DMSO (Fisher Chemicals).
Target cells for antigen presentation experiments. For these experi-
ments, pairs of target LCLs were generated from individual HLA-typed lab-
oratory donors by in vitro infection of peripheral blood B cells with recom-
binant strains of EBV generated by bacterial artificial chromosome cloning
(53). One LCL in each pair (referred to as the BZLF1  LCL) carried a
wild-type B95.8 virus genome, the other (referred to as the BZLF1  LCL)
carried a B95.8 genome that had been rendered incapable of lytic cycle en-
try by disruption of the BZLF1 gene (22). All LCLs were cultured in stan-
dard culture media, except in some experiments where late antigen expres-
sion in BZLF1  LCLs was inhibited by growth for 7 d in 200  M
acyclovir. The lytic antigen-positive and lytic antigen-negative status of
BZLF1  and BZLF1  LCLs in each pair was confirmed both by immuno-
blotting using selected human sera with strong lytic antigen reactivities (33)
and immunofluorescence staining with mAbs BZ1 to the IE antigen
BZLF1, R3 to the E antigen BMRF1, and L2 to the L antigen BALF4 (32).
Frequencies of antigen-positive cells were determined from counts on
 2,000 cells per cell line. Frequencies of BZLF1- and BMRF1-expressing
cells were very similar and only slightly higher than that of BALF4-express-
ing cells; typical percentages were between 2 and 5% for BZLF1 and
BMRF1 staining, and between 1.5 and 4.5% for BALF4 staining. No stain-
ing was ever detected in BZLF1  LCLs.
ELISPOT assays for antigen presentation experiments. The lytic
antigen-specific CD8  T cell clones were generated either from the
present panel of IM donors or from other IM patients as described previ-
ously (18); the only exceptions were the IE epitope-specific clones RBc 95
and RBc 18 that were generated by autologous LCL stimulation from a
healthy EBV carrier and the L epitope–specific clone IM73c4 that was gen-
erated by peptide stimulation from a rare memory cell in post-IM PBMCs.
The capacity of these CD8  T cell clones to recognize lytically infected
cells within LCLs of the relevant HLA type was measured by IFN 
ELISPOT assays using cytokine capture and detection reagents according to
the manufacturer’s instructions (Mabtech). In brief, anti-IFN   antibodies
were coated on the wells of a 96-well nitrocellulose plate and replicate wells
were seeded with 500 cloned CD8  T cells and 50,000 target cells of either
the BZLF1  LCL or, as a negative control, the paired BZLF1  LCL or, as
a positive control, the BZLF1  LCL in which 1, 2, or 5% of the cells had
been preincubated with an optimal concentration of the epitope peptide
and washed well before adding back to the untreated BZLF1  LCL popu-
lation. After incubation for 16 h, captured IFN  was detected with a biotin-
ylated anti-IFN  antibody followed by development with streptavidin
horseradish peroxidase complex and chromogenic substrate, and spots
counted using an automated plate counter (AID). Additional ELISPOT as-
says were performed to determine whether, in BZLF1  LCLs, antigens re-
leased from the subpopulation of cells in lytic cycle could be acquired by la-
tently infected cells in the same culture and represented via the HLA class I
pathway. In these experiments, BZLF1  LCL cells lacking the relevant
HLA restricting allele (donor cells) were mixed with an equal number of
BZLF1  LCL cells with the relevant HLA allele (recipient cells) and the
mixture cocultivated for 7 d, and then used as targets in ELISPOT assays ei-
ther without further manipulation or preexposed to an optimal concentra-
tion of epitope peptide immediately before the assay. The donor and recip-
ient LCLs alone served as negative control targets in such experiments, and
a BZLF1  LCL with the relevant HLA allele served as a positive control.
Assays of CD8  T cell functional avidity. CD8  T cell clones were
assayed for functional avidity using the ELISPOT assay of IFN  release to
quantitate antigen recognition. Target cells were BZLF1  LCLs of the ap-
propriate HLA type that had been preexposed to epitope peptide across a
range of 10-fold dilutions from 10 5 to 10 13 M, washed well and used im-
mediately as targets. Functional avidity was calculated from a graph of rec-
ognition versus peptide concentration as that concentration mediating 50%
optimal recognition.
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